Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

This study has been terminated.
(Lack of improved efficacy compared to historical controls, competing studies)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Rutgers, The State University of New Jersey ( University of Medicine and Dentistry of New Jersey ) Identifier:
First received: November 5, 2008
Last updated: September 23, 2013
Last verified: September 2013

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hydroxychloroquine may help docetaxel work better and kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving docetaxel together with hydroxychloroquine works in treating patients with metastatic prostate cancer.

Condition Intervention Phase
Prostate Cancer
Drug: docetaxel
Drug: hydroxychloroquine
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Rutgers, The State University of New Jersey:

Primary Outcome Measures:
  • Tumor Response Rate - Primary Endpoint is a 50% Decline in PSA or Normalization of PSA. [ Time Frame: 4 years ]
    We will use a two-stage optimal Simon's design with a 5% significance level and 80% power to detect an increase in response rate from 50% to 70%. The first stage will enroll 15 patients. If there are 8 or fewer responses among these 15 patients, we will consider the combination therapy to not be worthy of further study, and stop the trial. If we find 9 or more responses, we will proceed to the second stage, and accrual continues for a total of 43 patients. If we see 26 or fewer responses out of 43, then no further investigation of the drug is warranted. If we see 27 or more responses out of 43, then further investigation of the drug will be considered. The "expected" sample size of the trial is 23.5 with the null response rate of 50%.

Secondary Outcome Measures:
  • Time to Disease Progression [ Time Frame: 10 years ]
  • Overall Survival [ Time Frame: 10 years ]

Enrollment: 11
Study Start Date: December 2008
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Docetaxel and Hydroxychloroquine

Drug: Docetaxel 75 mg/m2 intravenously every 21 days on Day 1 of the treatment cycle

Drug: hydroxychloroquine 200 mg twice daily

A cycle is defined as an interval of 21 days.

Drug: docetaxel Drug: hydroxychloroquine

Detailed Description:



  • To assess the antitumor activity, in terms of tumor response rate, of docetaxel in combination with hydroxychloroquine in patients with metastatic, hormone-refractory, chemotherapy-naive prostate cancer.


  • To measure time to disease progression and overall survival.
  • To determine the feasibility and safety of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral hydroxychloroquine twice daily on days 1-21 and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days (up to 6 courses with docetaxel) in the absence of disease progression or unacceptable toxicity.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically confirmed prostate cancer

    • Metastatic disease, as demonstrated by bone scan and/or CT scan of the abdomen/pelvis
    • Must demonstrate disease progression after initial hormone therapy (including bicalutamide and flutamide)
    • No prior chemotherapy allowed
  • No known brain metastases


  • ECOG performance status 0-1
  • Life expectancy ≥ 6 months
  • ANC > 1,500/μL
  • Hemoglobin > 10 g/dL
  • Platelet count > 100,000/mm^3
  • Serum creatinine < 2.0 mg/dL or creatinine clearance > 50 mL/min
  • Total bilirubin normal
  • SGOT and/or SGPT < 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase < 2.5 times ULN
  • Fertile patients must use effective contraception during and for 3 months after completion of study therapy
  • No second primary malignancy except for most in situ carcinomas (e.g., adequately treated nonmelanoma carcinoma of the skin) or other malignancy treated ≥ 5 years ago with no evidence of recurrence
  • No history or symptoms of cardiovascular disease, including any of the following:

    • NYHA class II-IV cardiovacular disease within the past 6 months
    • Coronary artery disease
    • Arrhythmias
    • Conduction defects with risk of cardiovascular instability
    • Uncontrolled hypertension
    • Clinically significant pericardial effusion
    • Congestive heart failure
  • No uncontrolled intercurrent illness including ongoing active infection that would limit compliance with study requirements
  • No rheumatoid arthritis or systemic lupus erythematosus requiring treatment
  • No psoriasis or porphyria
  • No known HIV infection
  • No hypersensitivity to 4-aminoquinoline compounds, including hydroxychloroquine sulfate, chloroquine phosphate, and amodiaquine
  • No retinal or vision changes from prior 4-aminoquinoline compound use
  • No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
  • No known G-6PDH deficiency
  • Neurotoxicity ≤ grade 1


  • See Disease Characteristics
  • Recovered from all prior therapy
  • No prior taxane
  • At least 4 weeks since prior therapy (including surgery and radiotherapy)
  • At least 1 week since prior herbal supplements
  • At least 6 weeks since prior bicalutamide
  • At least 4 weeks since prior flutamide
  • No current hydroxychloroquine for treatment or prophylaxis

    • Prior hydroxychloroquine allowed
  • No other concurrent investigational or commercial agents or therapies, including chemotherapy, immunotherapy, hormonal cancer therapy, radiotherapy, surgery for cancer, or experimental therapy
  • Concurrent luteinizing-hormone releasing-hormone agonists allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00786682

United States, New Jersey
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, United States, 08690
Mountainside Hospital
Montclair, New Jersey, United States, 07042
Carol G. Simon Cancer Center at Morristown Memorial Hospital
Morristown, New Jersey, United States, 07962
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08903
St. Peters University Hospital
New Brunswick, New Jersey, United States, 08903
Overlook Hospital
Summit, New Jersey, United States, 07901
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Sponsors and Collaborators
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)
Principal Investigator: Mark Stein, MD Rutgers Cancer Institute of New Jersey
  More Information

Responsible Party: University of Medicine and Dentistry of New Jersey Identifier: NCT00786682     History of Changes
Other Study ID Numbers: CDR0000617998
P30CA072720 ( US NIH Grant/Contract Award Number )
CINJ-080805 ( Other Identifier: Cancer Institute of New Jersey )
Study First Received: November 5, 2008
Results First Received: September 23, 2013
Last Updated: September 23, 2013

Keywords provided by Rutgers, The State University of New Jersey:
stage IV prostate cancer
recurrent prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Antirheumatic Agents processed this record on April 21, 2017